Feb 3, 2022 8:00 am EST Achieve Life Sciences Announces Expansion of Cytisinicline Clinical Operations Team and Granting of Inducement Award
Feb 2, 2022 8:00 am EST Achieve Life Sciences Announces Participation in February Investor Conferences
Jan 25, 2022 8:00 am EST Achieve Life Sciences Announces Initiation of the Phase 3 ORCA-3 Clinical Trial Evaluating Cytisinicline for Smoking Cessation
Jan 6, 2022 8:30 am EST Achieve Life Sciences to Present at H.C. Wainwright BIOCONNECT Virtual Conference
Jan 4, 2022 8:30 am EST Achieve Life Sciences Announces Completion of Last Subject, Last Follow-Up Visit in Phase 3 ORCA-2 Trial of Cytisinicline for Smoking Cessation
Dec 22, 2021 8:30 am EST Achieve Life Sciences Announces $25 Million Loan Facility from Silicon Valley Bank to Fund Cytisinicline Smoking Cessation Clinical Development
Nov 23, 2021 8:30 am EST Achieve Life Sciences to Host Key Opinion Leader Panel on Smoking and e-Cigarette Cessation
Nov 22, 2021 8:30 am EST Achieve Life Sciences Announces Phase 3 ORCA-2 Trial of Cytisinicline in Smoking Cessation Clears Final Review by Data Safety Monitoring Committee (DSMC)
Nov 9, 2021 4:05 pm EST Achieve Reports Financial Results for Third Quarter 2021 and Provides Update on Cytisinicline Development
Nov 4, 2021 8:30 am EDT Achieve Life Sciences Announces Participation in November Investor Conferences